Journal of cardiovascular electrophysiology · 2026
Ventricular Tachycardia Ablation Outcomes in Patients With Previous Implantable Cardioverter-Defibrillator Insertion: A Multicenter Cohort Study.
СтатьяМногоцентровое исследованиеНаблюдательное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Al-Shammari Ali Saad, Singla Ankur, Rao Adishwar, Al Sakini Ahmed Sermed, Awashra Ameer, Khan Misha, Mutar Mohammed Tareq, Hamzah Khadeeja Ali, Al-Kaisey Ahmed, Al-Taii Haider, Ahmed Raheel, Syed Saif, Ahuja Keerat Rai
Аннотация
BACKGROUND: Catheter ablation is increasingly used in patients with ventricular tachycardia (VT) and an implantable cardioverter-defibrillator (ICD) device in situ, but its real-world safety and effectiveness remain underexplored in this high-risk population. We aim to evaluate in-hospital outcomes associated with catheter ablation in VT patients with a history of ICD implantation using a large, nationally representative dataset.
METHODS: We performed a retrospective cohort study using the National Inpatient Sample (2016-2021) to identify adult hospitalizations with VT and prior ICD device insertion. Patients were stratified into ablation and non-ablation groups. Propensity score matching was used to balance baseline characteristics. Primary outcome was in-hospital mortality; secondary outcomes included acute heart failure, ST-elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACE), and procedure-related complications.
RESULTS: Among 395,290 hospitalizations with VT and prior ICD, 4.9% underwent ablation. Catheter ablation remained independently associated with reduced in-hospital mortality (adjusted odds ratio [aOR] = 0.59; 95% CI: 0.48-0.74), acute heart failure (aOR = 0.59; 95% CI: 0.54-0.64), ST-elevation MI (aOR = 0.44; 95% CI: 0.36-0.54), and sepsis (aOR = 0.34; 95% CI: 0.26-0.45) (all p < 0.001). The composite MACE outcome also showed a reduced odds ratio for ablation (aOR = 0.76; 95% CI: 0.68-0.85; p < 0.001). However, ablation was also associated with higher odds of cardiac tamponade (aOR = 8.33; 95% CI: 5.92-11.73), cardiogenic shock (aOR = 1.36; 95% CI: 1.19-1.55), need for mechanical circulatory support (aOR = 5.36; 95% CI: 4.63-6.21), and prolonged hospital stay ≥ 7 days (aOR = 1.69; 95% CI: 1.57-1.82) (all p < 0.001).
CONCLUSION: In patients with VT and prior ICD implantation, catheter ablation is associated with improved in-hospital outcomes but higher procedural risks. These findings support its selective use in experienced centers capable of managing complications.
METHODS: We performed a retrospective cohort study using the National Inpatient Sample (2016-2021) to identify adult hospitalizations with VT and prior ICD device insertion. Patients were stratified into ablation and non-ablation groups. Propensity score matching was used to balance baseline characteristics. Primary outcome was in-hospital mortality; secondary outcomes included acute heart failure, ST-elevation myocardial infarction (STEMI), sepsis, major adverse cardiac events (MACE), and procedure-related complications.
RESULTS: Among 395,290 hospitalizations with VT and prior ICD, 4.9% underwent ablation. Catheter ablation remained independently associated with reduced in-hospital mortality (adjusted odds ratio [aOR] = 0.59; 95% CI: 0.48-0.74), acute heart failure (aOR = 0.59; 95% CI: 0.54-0.64), ST-elevation MI (aOR = 0.44; 95% CI: 0.36-0.54), and sepsis (aOR = 0.34; 95% CI: 0.26-0.45) (all p < 0.001). The composite MACE outcome also showed a reduced odds ratio for ablation (aOR = 0.76; 95% CI: 0.68-0.85; p < 0.001). However, ablation was also associated with higher odds of cardiac tamponade (aOR = 8.33; 95% CI: 5.92-11.73), cardiogenic shock (aOR = 1.36; 95% CI: 1.19-1.55), need for mechanical circulatory support (aOR = 5.36; 95% CI: 4.63-6.21), and prolonged hospital stay ≥ 7 days (aOR = 1.69; 95% CI: 1.57-1.82) (all p < 0.001).
CONCLUSION: In patients with VT and prior ICD implantation, catheter ablation is associated with improved in-hospital outcomes but higher procedural risks. These findings support its selective use in experienced centers capable of managing complications.